Supreme Court refuses to review Lovenox case

The U.S. Supreme Court on Monday refused to review a ruling that a patent from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) related to marketed anticoagulant Lovenox enoxaparin is unenforceable due to inequitable conduct. Last year, the U.S. Court of Appeals for the Federal Circuit affirmed a 2007 ruling by the U.S. District Court for the Central District of California that U.S. Patent No. RE38,743 covering low-molecular weight heparins is unenforceable. sanofi-aventis said it was "disappointed" with the decision and had no plans to pursue further legal action (See BioCentury Extra, Thursday, May 15, 2008). ...